Windtree Therapeutics Inc represents a commitment to advancing the field of respiratory medicine through innovative solutions. The company strives for excellence, driving breakthroughs in the treatment of respiratory diseases. With a focus on developing therapeutics for neonatal and pediatric patients, Windtree Therapeutics aims to improve the quality of life for these vulnerable populations. By leveraging their expertise and research capabilities, the company aims to revolutionize respiratory care and bring about positive change in the healthcare industry. Windtree Therapeutics remains dedicated to making a lasting impact and improving patient outcomes through their values of innovation, scientific rigor, and patient-centricity.

Windtree Therapeutics Inc is primarily present in the United States.

Some significant milestones achieved by Windtree Therapeutics Inc include the successful completion of a Phase 2 clinical trial for their lead product candidate, AEROSURF®, which showed positive results in treating respiratory distress syndrome in premature infants. Additionally, the company secured funding through multiple grants and partnerships to support further research and development initiatives. Windtree Therapeutics Inc also advanced their pipeline of potential therapies and received approvals for various patents related to their innovative technologies. With their continued dedication to improving patient care and advancing medical solutions, Windtree Therapeutics Inc has positioned itself as a leading player in the biopharmaceutical industry.

Windtree Therapeutics Inc, formerly known as Discovery Laboratories Inc, is a biotechnology company specializing in developing and commercializing products for respiratory diseases and other healthcare issues. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania. Windtree focuses on developing novel therapies using its proprietary technology platform, which includes advanced lipids and synthetic lung surfactant formulations. With a strong commitment to improving patient outcomes, Windtree Therapeutics aims to address unmet medical needs in respiratory care. The company's dedication to innovation and expertise in the field have positioned it as a leader in the development of respiratory therapies.

The main competitors of Windtree Therapeutics Inc in the market are companies like AstraZeneca, GlaxoSmithKline, and Novartis.

Windtree Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Windtree Therapeutics Inc is focused on developing and commercializing innovative therapeutics for respiratory diseases and other indications. Windtree Therapeutics Inc is dedicated to addressing unmet needs in patient care by leveraging its proprietary technology platform. With a focus on improving treatments for respiratory conditions, the company aims to advance its product pipeline to provide better outcomes for patients. Windtree Therapeutics Inc's commitment to innovation, strategic partnerships, and research and development drives its business model and enables the company to deliver novel therapeutic solutions in the healthcare industry.

مُعامل القيمة السوقية إلى الأرباح لـ Windtree Therapeutics هو ؜-٠٫٠٤.

مُعامِل القيمة إلى المبيعات Windtree Therapeutics هو 0.

نقاط جودة AlleAktien لـ Windtree Therapeutics هي 2/10.

لا يمكن حالياً حساب الإيرادات لـWindtree Therapeutics.

صافي الربح المتوقعة Windtree Therapeutics هو ؜-٧١٫٣٩ مليون. USD.

Windtree Therapeutics Inc is a biopharmaceutical company that focuses on developing therapies for respiratory diseases and lung disorders. The company utilizes an innovative technology platform called Aerosolized KL4 Surfactant to develop aerosolized medications that can directly target and treat affected areas in the lungs.

يوزع Windtree Therapeutics أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Windtree Therapeutics في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـWindtree Therapeutics هو US97382D3035.

رمز WKN لـ Windtree Therapeutics هو A2P3ZQ.

الرمز المُختصر لـ Windtree Therapeutics هو WINT.

خلال آخر 12 شهراً، دفعت Windtree Therapeutics توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع Windtree Therapeutics خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ Windtree Therapeutics هي .

Windtree Therapeutics يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

Windtree Therapeutics دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

Windtree Therapeutics يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 USD من Windtree Therapeutics المُعلن عنها في ٣‏/١١‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٣‏/١١‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ٣‏/١١‏/٢٠٢٤.

في العام 2023، وزعت Windtree Therapeutics 0 USD كأرباح أسهم.

يتم توزيع أرباح Windtree Therapeutics بالعملة USD.